Skip to main content

Branded

  • Study: PPIs shift NSAID stomach damage to small intestine; probiotics possible solution

    HAMILTON, Ontario — Proton-pump inhibitors may aggravate, not soothe, stomach discomfort created through chronic use of nonsteroidal anti-inflammatory drugs for such conditions as arthritis, according to research released Thursday.

    In a study published in the medical journal Gastroenterology, principal investigator John Wallace reported the extent of the hard-to-detect damage caused to the small intestine only recently has been discovered through use of small video cameras swallowed like pills.

  • Pfizer extends tender offer to acquire Icagen

    NEW YORK — After entering a definitive agreement to acquire biopharmaceutical company Icagen, Pfizer has extended its tender offer for all outstanding shares of common stock.

    Pfizer, which already has an 11% stake in Icagen, is offering the company a cash transaction of $6 per share. The tender offer, which was extended to Icagen through Pfizer's wholly owned subsidiary Eclipse Acquisition, expires at midnight on Sept. 1.

    All other terms and conditions of the tender offer remain unchanged.

  • Ragweed allergies high across nation; St. Louis med center offers steps toward relief

    ST. LOUIS — The St. Louis University Medical Center on Tuesday issued a step-by-step guide in tackling allergies, timely considering the recent uptick in ragweed allergies. According to Weather.com, weed allergens are particularly high right now across much of the continental United States.

    The guidelines:

  • Eisai drug shows 'significant' reduction in epileptic seizures

    WOODCLIFF LAKE, N.J. — A drug under late-stage clinical development by Eisai reduced the frequency of seizures in patients with epilepsy, according to trial results the drug maker presented Tuesday at the 2011 International Epilepsy Congress.

  • Rx Response puts tool into play in communities impacted by Irene

    WASHINGTON — Rx Response late Monday announced it has activated its Pharmacy Reporting Status Tool to aid storm managers and people in communities affected by Hurricane Irene.

  • Federal court issues rulings in favor of Teva in MS drug case

    JERUSALEM — A federal court has acted in favor of Teva Pharmaceutical Industries in the drug maker's patent infringement case against several generic drug companies seeking to market versions of its multiple sclerosis drug.

  • Craig Eagle joins corporate advisory board at Provectus

    KNOXVILLE, Tenn. — The VP strategic alliances and partnerships for Pfizer's oncology division has joined the corporate advisory board at a development-stage oncology and dermatology biopharmaceutical company.

    Provectus Pharmaceuticals said that the company will benefit from Craig Eagle's "vast experience in drug development" as the drug maker seeks to commercialize its cancer and dermatological therapies.

  • FDA accepts application for opioid-induced constipation drug

    TARRYTOWN, N.Y. — The Food and Drug Administration has accepted a regulatory approval application from Progenics Pharmaceuticals and Salix Pharmaceuticals seeking an additional approval for a pain drug.

    The two drug makers announced Tuesday that the FDA had accepted their supplemental new drug application for Relistor (methylnaltrexone bromide), an injectable drug for treating opioid-induced constipation.

X
This ad will auto-close in 10 seconds